NEW PROVIDENCE, N.J., April 1, 2019 /PRNewswire/ -- Evolution Research Group ("ERG"), a leading independent clinical research site company serving pharmaceutical companies and clinical research organizations, with an expertise in early- and late-stage neuroscience drug development, has acquired Rochester, NY-based Finger Lakes Clinical Research ("FLCR"), a clinical research facility specializing in pediatric and adult central nervous system trials for major national and international pharmaceutical firms.
Founded and directed by Principal Investigator Sarah D. Atkinson, MD, FLCR has conducted trials across a broad range of illnesses, including anxiety disorders, ADHD, depression, bipolar disorder, schizophrenia and other mental illnesses since its founding in 2002.
"We are very excited to welcome Dr. Atkinson and FLCR to the ERG family," said Lori Wright, CEO of ERG. "The addition of FLCR expands ERG's geographic capabilities in both adult and pediatric outpatient trials and further enhances ERG's growing service offerings to our clients." Dr. Atkinson added, "My staff and I are delighted to be joining ERG. Its excellent reputation, high quality standards, clinical expertise, and strong business development capabilities, make ERG the ideal partner for FLCR in this next chapter of our own growth."
Michael Farah, Chairman of ERG and Partner at Linden Capital Partners, added, "Dr. Atkinson is a highly regarded Principal Investigator who has built a high quality and incredibly successful practice that is complementary to ERG. FLCR expands ERG's footprint in growing psychiatric therapeutic areas and provides additional diversification which will allow us to further service our world-wide clients to develop important new therapies."
Honigman LLP and Kirkland & Ellis LLP served as legal advisors to ERG.
Fried Frank served as legal advisors to FLCR.
About Evolution Research Group
Evolution Research Group, LLC is comprised of 13 wholly owned and operated clinical research units, and an established network of affiliated clinical research sites. ERG conducts a wide range of simple and highly complex trials in specialized populations, including those suffering from psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency, and hepatic impairment, as well as normal healthy volunteers.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on investing in the healthcare industry. Linden's strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.
SOURCE Evolution Research Group, LLC